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P
Myocardial Infarction
volution in Cardiovascular Care for
lderly Patients With Non–ST-Segment
levation Acute Coronary Syndromes
esults From the CRUSADE National Quality Improvement Initiative
aren P. Alexander, MD* Matthew T. Roe, MD, MHS,* Anita Y. Chen, MS,* Barbara L. Lytle, MS,*
harles V. Pollack, JR, MD, MA,† Joanne M. Foody, MD,‡ William E. Boden, MD,§
idney C. Smith, JR, MD, W. Brian Gibler, MD,¶ E. Magnus Ohman, MD,
ric D. Peterson, MD, MPH,* for the CRUSADE Investigators
urham and Chapel Hill, North Carolina; Philadelphia, Pennsylvania; New Haven and Hartford, Connecticut;
nd Cincinnati, Ohio
OBJECTIVES This study evaluated the impact of age on care and outcomes for non–ST-segment elevation
acute coronary syndromes (NSTE ACS).
BACKGROUND Recent clinical trials have expanded treatment options for NSTE ACS, now reflected in
guidelines. Elderly patients are at highest risk, yet have previously been shown to receive less
care than younger patients.
METHODS In 56,963 patients with NSTE ACS at 443 U.S. hospitals participating in the Can Rapid
Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early
Implementation of the American College of Cardiology/American Heart Association
Guidelines (CRUSADE) National Quality Improvement Initiative from January 2001 to
June 2003, we compared use of guidelines-recommended care across four age groups: 65,
65 to 74, 75 to 84, and 85 years. A multivariate model tested for age-related differences in
treatments and outcomes after adjusting for patient, provider, and hospital factors.
RESULTS Of the study population, 35% were 75 years old, and 11% were 85 years old. Use of acute
anti-platelet and anti-thrombin therapy within the first 24 h decreased with age. Elderly
patients were also less likely to undergo early catheterization or revascularization. Whereas use
of many discharge medications was similar in young and old patients, clopidogrel and
lipid-lowering therapy remained less commonly prescribed in elderly patients. In-hospital
mortality and complication rates increased with advancing age, but those receiving more
recommended therapies had lower mortality even after adjustment than those who did not.
CONCLUSIONS Age impacts use of guidelines-recommended care for newer agents and early in-hospital care.
Further improvements in outcomes for elderly patients by optimizing the safe and early use
of therapies are likely. (J Am Coll Cardiol 2005;46:1479–87) © 2005 by the American














he optimal management of patients with acute coronary
yndromes (ACS) continues to evolve rapidly with the
evelopment of new therapeutics and strategies of care. The
merican College of Cardiology/American Heart Associa-
ion (ACC/AHA) recently updated their treatment guide-
ines for non–ST-segment elevation (NSTE) ACS to reflect
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ort. Drs. Roe, Pollack, Boden, Smith, Gibler, Ohman, and Peterson have served
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he CRUSADE National Quality Improvement Initiative.a
Manuscript received March 3, 2005; revised manuscript received April 29, 2005,
ccepted May 3, 2005.hese advancements (1,2). The guidelines emphasize the
eed to provide intensive and early medical and interven-
ional therapy, particularly for those at highest risk for
hort-term events (3).
See page 1488
Prior work has shown that elderly patients with NSTE
CS are at greater risk of mortality and morbidity than
ounger patients, and that medication and catheter-based
herapies have the greatest benefit on outcomes among
atients at highest risk (4,5). Studies from the 1990s
ocumented widespread underuse of cardiac medications in
lderly populations with ST-segment elevation myocardial
nfarction (6–13), and many have emphasized the need for
vidence-based cardiac care in all patients, particularly
lderly patients (14,15). Recent efforts to increase physician
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Care of Elderly ACS Patients in the CRUSADE National Quality Improvement Initiative October 18, 2005:1479–87ecommended therapies for NSTE ACS may have altered
urrent practice patterns for elderly ACS patients.
This analysis compares contemporary in-hospital treat-
ent patterns and outcomes of elderly patients with NSTE
CS with their younger counterparts. We used the Can
apid Risk Stratification of Unstable Angina Patients
uppress Adverse Outcomes With Early Implementation of
he ACC/AHA Guidelines (CRUSADE) National Quality
mprovement Initiative database to address this question
cross 443 hospitals in 46 states (16). Using this large
atabase, we provide specific insight into the early and
ischarge use of medications, reported contraindications,
se of an invasive strategy, and the relationship between
uidelines-recommended care and mortality in young and
ld patients.
ETHODS
opulation. The CRUSADE initiative is an ongoing da-
abase of patients with high-risk NSTE ACS admitted to
.S. hospitals. The current analysis includes 56,963 patients
ho were treated at 443 hospitals between January 1, 2001,
nd June 30, 2003. Inclusion criteria for participation in the
atabase were ischemic symptoms lasting 10 min com-
ined with positive cardiac markers or ischemic ST-segment
lectrocardiograph changes (ST-segment depression or
ransient ST-segment elevation). Patients were ineligible for
he CRUSADE initiative if they transferred into a partici-
ating hospital 24 h after the last episode of ischemic
ymptoms. Patients were ineligible for this analysis if they
ransferred out of a participating hospital resulting in
ncomplete data on acute care, in-hospital outcomes, and
ischarge therapies (n  8,385), or had missing age infor-
ation (n  76), leaving a final population of 56,963
atients.
ata collection. Hospitals participating in the CRU-
ADE initiative collect detailed process of care and in-
ospital outcomes data through retrospective chart review.
ata are collected anonymously during the initial hospital-
zation, and because no patient identifiers are collected,
ndividual informed consent is not required. The institu-
Abbreviations and Acronyms
ACC/AHA  American College of Cardiology/
American Heart Association
BP  blood pressure
CHF  congestive heart failure
CRUSADE  Can Rapid Risk Stratification of Unstable
Angina Patients Suppress Adverse
Outcomes With Early Implementation of
the American College of Cardiology/
American Heart Association Guidelines
NSTE ACS  non–ST-segment elevation acute coronary
syndromesional review board of each institution approves participa- eion in the CRUSADE initiative. Data collected include the
se of acute medications (within 24 h of presentation), use
nd timing of invasive cardiac procedures, laboratory results,
hysician and hospital characteristics, and discharge thera-
ies and interventions.
ata definitions. Charts were abstracted using specified
efinitions from the CRUSADE initiative data collection
orms. Hypertension was defined as systolic blood pressure
BP) 140 mm Hg, diastolic BP 90 mm Hg on repeated
easurements, or hypertension chronically treated with
nti-hypertensive medications. Renal insufficiency was de-
ned by serum creatine 2.0 mg/dl, creatinine clearance
30 ml/min, or need for renal dialysis. Signs of congestive
eart failure (CHF) were indicated by exertional dyspnea,
rthopnea, shortness of breath, labored breathing, fatigue
ither at rest or with exertion, rales in more than one-third
f the lung fields, elevated jugular venous pressure, S3
allop, or pulmonary congestion on X-ray believed to
epresent cardiac dysfunction. Hyperlipidemia was defined
s total cholesterol 200 mg/dl or treatment with a lipid-
owering agent. Recurrent infarction was defined by clinical
igns and symptoms of a new infarction distinct from the
resenting ischemic event and meeting predefined cardiac
arker and electrocardiogram criteria. Cardiogenic shock
as defined by systolic BP 90 mm Hg for 1 h, not
esponsive to fluid resuscitation alone, and thought to be
econdary to cardiac dysfunction. Transfusions were defined
s any non-autologous transfusion(s) of either whole blood
r packed red blood cells. The attending physician who
rimarily cared for the patient during the hospitalization
as determined by the most frequent and consistent nota-
ions in the medical record; specialties included cardiologist,
nternist, family practitioner, and other.
ontraindications. The CRUSADE initiative collects in-
ormation regarding contraindications to all guidelines-
ecommended medications that were clinically documented
n the patient’s medical record. Specific clinical contraindi-
ations for given agents were as follows: aspirin (intolerance,
llergy, active bleeding/history of bleeding, ulcer or serious
astrointestinal or genitourinary bleeding, dyspepsia, plate-
et count 100,000/mm3, anemia, use of warfarin); beta-
lockers (allergy/hypersensitivity, bradycardia, heart block
reater than first degree, cardiogenic shock, hypotension,
hronic obstructive pulmonary disease/asthma/broncho-
pasm); glycoprotein IIb/IIIa inhibitors (active/recent
leeding, allergy/intolerance/hypersensitivity, platelet count
100,000/mm3, severe hypertension, recent major surgery,
ecent stoke/any previous hemorrhagic stroke, serum crea-
ine 4.0 mg/dl, severe comorbid illness); heparin (active/
ecent bleeding, platelet count 100,000/mm3, ulcer or
erious gastrointestinal or genitourinary bleeding, history of
nown heparin induced thrombocytopenia, severe comorbid
llness); lipid-lowering agents (allergy/hypersensitivity, he-
atic or renal dysfunction, abnormal liver function test
esults, primary biliary cirrhosis); angiotensin-converting
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October 18, 2005:1479–87 Care of Elderly ACS Patients in the CRUSADE National Quality Improvement Initiativeory of angioedema, impaired renal function, hypotension,
yperkalemia, pregnancy, liver disease). Importantly, be-
ond this pre-specified list, we allowed clinicians to docu-
ent contraindications that precluded them from treating a
atient. This conservative approach ensured that medication
se was assessed only among patients with true eligibility for
ach therapy.
utcomes. Acute and discharge use of ACC/AHA
uidelines-recommended therapies was then determined for
hose patients in our population who had indications but no
eported contraindications for each therapy (Appendix)
1,2). We considered only those therapies receiving a class
A (evidence and/or general agreement that a given proce-
ure or treatment is useful and effective from data derived
rom multiple randomized clinical trials that involved large
umbers of patients) or class IB (data derived from a limited
umber of randomized trials that involved small numbers of
atients or from careful analyses of non-randomized studies
r observational registries) designation. All decisions re-
arding the use of medications or procedures were made by
he treating physicians. We examined early use of medica-
ions, defined as those administered within 24 h of admis-
ion, and at discharge. Early medications included aspirin,
lopidogrel, beta-blockers, heparin, low-molecular-weight
eparin, and platelet glycoprotein IIb/IIIa inhibitors (1).
arly invasive strategy, defined as cardiac catheterization
ithin 48 h of admission, was also determined. Discharge
edications included aspirin, clopidogrel, beta-blockers,
ngiotensin-converting enzyme inhibitors (with an ejection
raction 40%, or the presence of diabetes mellitus or
ypertension), and lipid-lowering agents (with hyperlipid-
mia or low-density lipoprotein 100 mg/dl) per ACC/
HA guidelines recommendations (1). In-hospital clinical
utcomes of interest included in-hospital mortality, myo-
ardial infarction, CHF, recurrent stroke, revascularization,
nd bleeding requiring transfusion.
nalysis. In-hospital care patterns and outcomes were
ompared between groups of relatively older and younger
atients with NSTE ACS. We clustered patients into four
ge groups: 65, 65 to 74, 75 to 84, and 85 years old; in
ur analysis, young patients refers to those 65 years of age.
e compared patients’ baseline demographics, clinical
haracteristics, care patterns, and in-hospital outcomes, as
ell as the features of the admitting hospital. Continuous
ariables were reported as means with standard deviations,
nd categorical variables were reported as percentages.
ignificance was determined using chi-square tests and
ruskal-Wallis tests for categorical and continuous vari-
bles, respectively.
For medications, interventions, and in-hospital clinical
utcomes, we used generalized estimating equations to
djust for patient comorbidity and provider characteristics.
eneralized estimating equations provided a variant of the
ultiple logistic regression model, through which we were
ble to adjust for the clustering that results from patients
dmitted to the same hospital being more similar to each 1ther than to those admitted to other hospitals (17). The
odel also incorporated a broad range of patient and
ospital characteristics that included insurance type (Medi-
are/Medicaid, self/none, or health maintenance organiza-
ion/private), age, female gender, body mass index, white
ace, family history of coronary artery disease, hypertension,
iabetes, current/recent smoker, hyperlipidemia, prior myo-
ardial infarction, prior percutaneous coronary intervention,
rior coronary artery bypass grafting surgery, prior CHF,
rior stroke, renal insufficiency, ST-segment depression,
ransient ST-segment elevation, signs of CHF at presenta-
ion, heart rate, systolic blood pressure, total number of
ospital beds, teaching versus academic institution, and
ardiologist care. From the multivariable analyses, the effect
f age was then determined after adjustment for confound-
ng factors between comparison groups.
Finally, we explored in-hospital mortality for older and
ounger patients after adjusting for baseline characteristics
nd the number of recommended ACS treatments they
eceived in which we modeled the number of recommended
reatments as an ordinal variable. Five treatments were
onsidered: 1) early aspirin, 2) early beta-blockers, 3) early
eparin (any), 4) early glycoprotein IIb/IIIa inhibition and
atheterization within 48 h, and 5) catheterization within
8 h. All analyses were performed with SAS software
ersion 8.2 (SAS institute Inc., Cary, North Carolina).
ESULTS
emographics and clinical characteristics of the 56,963
STE ACS patients are shown by four age groups (Table
). The majority of our population was age 65 years or older
58%), with 11.2% being 85 years old, and the oldest
atient being 103 years old. The vast majority of patients
ad positive cardiac markers (85%), and many had ST-
egment depression at presentation as well (40%). Elderly
atients were more likely to have positive markers and CHF
t presentation than younger patients (91.6% positive mark-
rs and 41.4% CHF in the 85 age group). With advancing
ge, elderly patients had a declining prevalence of cardiac
isk factors (diabetes, hyperlipidemia, smoking), but an
ncreasing history of known cardiac disease (prior CHF,
yocardial infarction, or coronary artery bypass grafting). In
ddition, elderly patients had more comorbidity (renal
nsufficiency, stroke, and hypertension). Thus, among an
lready high-risk population, older age predicted a greater
urden of comorbidity and disease severity at presentation.
n addition, older patients were more likely to be treated at
maller, non-academic hospitals, and less likely to be treated
y specialists.
With advancing age, medication contraindications were
eported more often for early and discharge therapies.
mong medications, contraindication rates varied from
.6% for contraindications to lipid-lowering agents to
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Care of Elderly ACS Patients in the CRUSADE National Quality Improvement Initiative October 18, 2005:1479–87raindication rates tended to increase with advancing patient
ge (Fig. 1).
The percentages and adjusted odds ratios for use among
ligible patients of early in-hospital medications by age
roup are shown in Table 2 and Figure 2A. In-hospital use
f aspirin and beta-blockers had small but statistically
ignificant reductions in use past 65 years of age, and
eparin had a small but significant reduction in use past 85
ears of age. Age had its most notable impact on use of acute
lopidogrel and platelet glycoprotein IIb/IIIa inhibitors.
espite 92% of patients age 85 years having positive

















CHF at presentation 12.5
ECG changes at presentation
ST-segment depression 38.0
Transient ST-segment elevation 12.8
Positive cardiac markers 86.7
Provider factors (%)




Bed size (mean  SD) 422  19
*All p values  0.0001; data presented as percentages unles
Council of Teaching Hospitals.
CABG  coronary artery bypass grafting; CHF  conge
infarction; PCI  percutaneous coronary intervention; SD 
igure 1. Contraindications to short-term therapies by age and drug type.
ncludes contraindications defined by clinical criteria or provider discretion
hat use of the agent was contraindicated in specific patients. Open bars 65 years old; grey bars  65 to 74 years old; ruled bars  75 to 84 years
ld; black bars  85 years old. GP  glycoprotein.ardiac markers, only 30% received clopidogrel, whereas
2.8% received platelet glycoprotein IIb/IIIa inhibitors.
During their hospitalization, elderly patients were less
ikely to undergo early invasive care or revascularization
rocedures (Fig. 2B, Table 2). The use of an early invasive
trategy, defined as diagnostic coronary angiography within
8 h of admission, tapered with age starting around the age
f 70 years (Fig. 2B). Past the age of 75 years, only 40%
nderwent early invasive care, and past age 85 that number
as 20%. We also examined therapies used among inva-
ively managed patients. As seen in Table 3, use of clopi-
ogrel and glycoprotein IIb/IIIa inhibitors was significantly
ower among invasively managed elderly patients compared
ith similarly managed younger patients.
The risk of in-hospital death increased continuously with
atient age from 1.9% for age 65 to 11.5% for age 85
ears (Fig. 2C). After adjustment for patient and hospital
actors, the odds ratio of in-hospital death for older age
roups compared with age 65 was 1.88 for patients age 65
o 74 years, 2.46 for those ages 75 to 84 years, and 3.00 for
hose age 85 years. (Table 4) Other adverse in-hospital
vents also increased steadily with age, and included recur-
ent myocardial infarction, CHF, stroke, and transfusion.
ost notable among these was CHF, which increased
hree-fold between age 65 and 85 years (unadjusted rates:




























413  200.9 408  203.1 393  206.4
rwise indicated. †Academic hospitals were members of the
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October 18, 2005:1479–87 Care of Elderly ACS Patients in the CRUSADE National Quality Improvement Initiativeaspirin, heparin, -blockers, glycoprotein IIb/IIIa inhi-
ition, and catheterization) was also associated with a
ower likelihood of in-hospital mortality (Fig. 3). After
able 2. Early (24 h of Admission) Medications and Early Pro
<65 yrs 65–74 yrs
% % Adjusted OR (95% C
edications
Aspirin 93.1 90.6 0.86 (0.80–0.94)
Beta-blockers 79.7 78.1 0.94 (0.89–1.00)
Heparin, any 84.8 83.7 1.07 (1.00–1.14)
Clopidogrel 45.2 40.8 0.93 (0.88–0.98)
GP IIb/IIIa inhibitors 44.6 35.9 0.90 (0.84–0.95)
rocedures
Cath 83.1 77.8 0.95 (0.88–1.02)
Cath 48 h 62.8 53.5 0.88 (0.83–0.94)
PCI 50.4 42.2 0.89 (0.84–0.95)
PCI 48 h 38.7 29.6 0.88 (0.82–0.94)
CABG 14.5 16.8 1.37 (1.27–1.48)
All p values  0.0001; all medication use in patients without contraindications (see
mong those with no contraindications, thus the number of patients vary slightly from
f patients range from 20,731 to 23,694, and among patients age 85, the number
Cath  catheterization; CI  confidence interval; GP  glycoprotein; OR  od
igure 2. (A) Short-term use of medications within the first 24 h of adm
iagnostic and invasive procedures by age. (C) In-hospital mortality
ontraindications). ACE  angiotensin-converting enzyme; CABG  coronary
percutaneous coronary intervention.djusting for other factors, in-hospital death was lowered
y an increasing use of recommended therapies for both
atients age 75 years and patients age 75 years alike
ral Care (48 h of Admission) by Age Group*
75–84 yrs >85 yrs
% Adjusted OR (95% CI)† % Adjusted OR (95% CI)†
89.6 0.87 (0.80–0.96) 88.5 0.92 (0.81–1.04)
76.1 0.89 (0.84–0.95) 75.8 0.96 (0.88–1.04)
80.4 0.99 (0.92–1.06) 72.8 0.77 (0.70–0.85)
35.0 0.83 (0.78–0.88) 29.9 0.82 (0.76–0.87)
25.8 0.68 (0.63–0.73) 12.8 0.39 (0.35–0.44)
64.0 0.60 (0.55–0.65) 32.2 0.20 (0.17–0.23)
40.4 0.63 (0.59–0.67) 18.0 0.25 (0.22–0.28)
33.4 0.74 (0.68–0.80) 18.8 0.43 (0.39–0.49)
21.0 0.68 (0.63–0.73) 10.1 0.37 (0.32–0.42)
12.1 1.02 (0.93–1.12) 3.1 0.25 (0.20–0.30)
dix). †In comparison with patients 65 years of age. All percentages represent use
ge group total shown in Table 1. For example, among patients age 65, the number
ients range from 4,837 to 6,401.
io; other abbreviations as in Table 1.
by age (among those with no contraindications). (B) Use of in-hospital
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Care of Elderly ACS Patients in the CRUSADE National Quality Improvement Initiative October 18, 2005:1479–87odds ratio, 0.79; 95% confidence interval, 0.75 to 0.83;
nd odds ratio, 0.71; 95% confidence interval, 0.67 to
.75, respectively). A formal test for interaction between
reatment and age was significant because of the larger
ifference in mortality between younger and older pa-
ients given fewer therapies compared with those given all
ve therapies. This indicates a similar or greater impact
f treatment on outcomes in elderly patients.
For those who survived to hospital discharge, percentages
nd adjusted odds ratios for use of discharge medications by
ge group are shown only among those with no reported
ontraindications and with specific indications (Table 5 and
ig. 2D). After adjustment, discharge use of aspirin, beta-
lockers, and angiotensin-converting enzyme inhibitors was
ot influenced by patient age. However, lipid-lowering
gents and clopidogrel use were significantly lower in elderly
atients than in younger patients.
ISCUSSION
he ACC/AHA guidelines for the treatment of NSTE
CS do not alter therapeutic recommendations based on
ge, apart from encouraging attention to comorbidities,
references, and appropriate dosing of medications in el-
erly patients (1,2). In contrast to these guidelines, however,
e found that use of many recommended therapies was
ower among elderly patients even after controlling for
ontraindications and comorbidities. Remaining age gaps
ere particularly notable in three areas: 1) early use of
ntravenous medications, 2) use of invasive care, and 3) use
able 3. Early Clopidogrel and Glycoprotein IIb/IIIa Inhibitor
se in Patients Managed With Early Invasive Strategy (Cath
48 h From Admission) Versus Conservative Care (Cath
48 h After Admission or No Cath)*
<65 yrs 65–74 yrs 75–84 yrs >85 yrs
lopidogrel
Overall 45.2 40.8 35.0 29.9
Early invasive (%) 55.0 51.4 47.8 51.0
Conservative (%) 30.8 30.6 28.1 26.5
P IIb/IIIa inhibitors
Overall 44.6 35.9 25.8 12.8
Early invasive (%) 58.8 51.9 45.5 42.8
Conservative (%) 22.1 18.4 13.4 7.0
In patients without contraindications (see Appendix) and alive at discharge (patient
enominator varies slightly from total n for age group).
Abbreviations as in Table 2.
able 4. In-Hospital Outcomes After Acute Coronary Syndrome
Outcomes
<65 yrs 65–74 yrs
% % Adjusted OR (95% CI)†
eath 1.9 4.6 1.88 (1.65–2.14)
epeat MI 2.5 3.5 1.22 (1.08–1.37)
HF 5.1 9.4 1.29 (1.18–1.40)
troke 0.5 1.0 1.94 (1.50–2.51)
lood transfusion 10.1 17.9 1.64 (1.52–1.76)All p values 0.0001. †In comparison with patients 65 years of age.
Abbreviations as in Table 2.f lipid-lowering agents and clopidogrel at discharge. We
onsider reasons and implications for remaining age gaps in
uidelines-recommended care.
arly use of medications. Age had a relatively modest
mpact on the early use of aspirin and beta-blockers.
owever, the early use of heparin, platelet glycoprotein
Ib/IIIa inhibitors, and clopidogrel decreased significantly
mong those age 75 years. The remaining gaps in recom-
ended care may originate from uncertainty regarding the
mpact of age on expected treatment effects (18,19). How-
ver, randomized clinical trials have found that unfraction-
ted heparin and low-molecular-weight heparin are effective
n both young and old patients (20–22). Similarly, evidence
lso shows a benefit of platelet glycoprotein IIb/IIIa inhib-
tors in young and elderly patients with electrocardiograph
hanges or positive enzymes regardless of age, particularly if
ndergoing invasive management (23,24).
Delayed identification of ACS in elderly patients may
urther explain lower use of early therapies. Elderly patients
re much less likely to present with classic chest pain, so
iagnosis may wait until cardiac markers are elevated (25).
n addition, elderly patients often have ACS coexisting with
ther acute illnesses, such as CHF or pneumonia, which
ay be the focus of initial care. However, because recurrent
vents are most likely to occur early in the hospitalization,
his gap in early use of therapies contributes to adverse
hort-term outcomes such as reinfarction, CHF, and death.
ge*
75–84 yrs >85 yrs
Adjusted OR (95% CI)† % Adjusted OR (95% CI)†
.3 2.46 (2.14–2.83) 11.5 3.00 (2.53–3.55)
.0 1.36 (1.18–1.56) 4.1 1.39 (1.18–1.63)
.5 1.56 (1.42–1.71) 16.7 1.62 (1.45–1.80)
.3 2.41 (1.86–3.13) 1.3 2.29 (1.63–3.22)
.6 1.65 (1.52–1.79) 15.7 1.14 (1.02–1.27)
igure 3. Adjusted in-hospital mortality among older and younger patients
ndergoing an early invasive strategy by the number of guideline recom-
endations applied (cardiac catheterization, short-term aspirin, short-term
eta-blocker, short-term heparin, and short-term glycoprotein IIb/IIIa
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October 18, 2005:1479–87 Care of Elderly ACS Patients in the CRUSADE National Quality Improvement InitiativePhysicians may also withhold therapy in elderly patients
ecause of safety concerns arising from comorbidity and
otential drug contraindications with age (Fig. 1). Age-
elated alterations in drug clearance increase bleeding risks
26). However, we found that use was still lower in elderly
atients after excluding those with investigator-documented
on-eligibility. Safety concerns should be considered in
ight of the potential harm caused by withholding effective
herapies in high-risk elderly patients.
ess invasive care. The use of an invasive management
trategy declines most precipitously with age. In the CRU-
ADE initiative, 50% of patients over the age of 65 years
nd only 11.2% of patients over the age of 85 years received
arly invasive care, despite 90% having positive cardiac
arkers. This conservative management of elderly ACS
atients is similar to that found in prior studies (27).
lthough the debate about the ideal management for ACS
ontinues, evidence from recent studies confirms a benefit of
n early invasive approach in both young and old patients
28–31). The Treat Angina with Aggrastat and Determine
ost of Therapy with an Invasive or Conservative Strategy
TACTICS) Thrombolysis In Myocardial Infarction
TIMI)-18 trial found an early invasive strategy conferred a
6% relative reduction in death or myocardial infarction at
ix months in patients with NSTE ACS older than 75 years
f age who received early invasive management compared
ith those treated with a conservative management strategy
32). Similarly, the Trial of Invasive versus Medical therapy
n Elderly patients (TIME) study (33,34) and the Alberta
rovincial Project for Outcomes Assessment in Coronary
eart Disease (APPROACH) study emphasized that older
atients who underwent aggressive revascularization thera-
ies had greater absolute risk reductions than younger
atients (35).
Although patient preferences may also play a role in the
onservative care of elderly patients, most elderly patients
re willing to consider revascularization if recommended by
heir physicians (36). Thus, increasing the use of early
nvasive care and revascularization may be another oppor-
unity for improving outcomes for elderly patients with
STE ACS.
ischarge medications. The discharge use of aspirin,
able 5. Discharge Medications by Age Group*
Medications
<65 yrs 65–74 yrs
% % Adjusted OR (95% CI
spirin 91.4 89.7 1.00 (0.92–1.08)
eta-blockers 83.6 83.0 0.97 (0.90–1.05)
CE inhibitors‡ 61.0 60.7 0.98 (0.92–1.03)
lopidogrel§ 58.3 53.0 0.89 (0.84–0.94)
ipid-lowering agents 82.0 80.5 0.92 (0.86–1.00)
Discharge medication use only in patients without contraindications (see Appendix)
omparison with patients 65 years of age. ‡p values  NS; for congestive heart fai
nterventional procedures. For history of hyperlipidemia or measured LDL 100 m
ACE  angiotensin-converting enzyme; other abbreviations as in Table 2.eta-blockers, and angiotensin-converting enzyme inhibi- fors did not decline with advancing age, suggesting that age
aps have narrowed over time in the use of these discharge
edications (7,11–13). The limited use of lipid-lowering
gents in elderly patients was the most notable finding
mong discharge medications. Although debate continues
egarding the benefit of lipid-lowering drugs in the 85
ears age group, their benefits in patients of all ages have
een confirmed in two large recent studies (37,38). Mount-
ng evidence confirms benefit from lipid-lowering therapy in
he short term after ACS, such that even those with limited
ife expectancy will benefit (39).
The use of clopidogrel at discharge largely parallels the
se of an invasive strategy during hospitalization in elderly
atients. Most notably, the CURE study found that use of
lopidogrel after ACS without invasive procedures was
ffective in reducing death, myocardial infarction, and
troke in both young and older patients (40–42).
tudy limitations. The CRUSADE initiative is an obser-
ational study, thus unmeasured biases that influence the
se of therapies may not have been captured. Specifically,
ontraindications were obtained during chart abstraction,
ot directly from the care team. However, this limitation
hould apply equally to patients of all ages, thereby mini-
ally affecting observations across age groups. The CRU-
ADE initiative reports in-hospital outcomes, so conclu-
ions about long-term mortality and quality of life
mplications for adherence to guidelines recommendations
annot be made from these data.
ONCLUSIONS
ptimizing the care of elderly patients with NSTE ACS is
timely imperative given the aging of the population.
pplying evidence to the treatment of elderly patients falls
hort of recommendations in several areas. Physicians are
nderstandably cautious regarding the application of newer
herapies and early invasive care to high-risk elderly pa-
ients, and concerns over risks and side effects influence
ractice (43). Thus, future work on early recognition of ACS,
afe application of acute treatments, and the use of secondary
reventions in elderly patients should enable providers to
75–84 yrs >85 yrs
% Adjusted OR (95% CI)† % Adjusted OR (95% CI)†
87.9 0.98 (0.89–1.08) 85.6 1.03 (0.90–1.17)
82.4 0.97 (0.89–1.05) 82.2 1.06 (0.97–1.16)
59.5 0.94 (0.88–1.00) 60.2 1.01 (0.93–1.11)
47.5 0.82 (0.77–0.87) 40.5 0.80 (0.77–0.87)
75.6 0.79 (0.73–0.85) 65.2 0.59 (0.53–0.66)
ive at discharge (patient denominator varies slightly from total n for age group). †In
ection fraction 40%, diabetes mellitus, or hypertension. §Among patients without)†
and al
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PPENDIX
or the class IA/IB recommended hospital and discharge
edications from the ACC/AHA guidelines for the man-
gement of patients with unstable angina and non–ST-
egment elevation myocardial infarction, please see the
nline version of this article.
